Literature DB >> 9098656

Drug-induced movement disorders.

F J Jiménez-Jiménez1, P J García-Ruiz, J A Molina.   

Abstract

Parkinsonism, tremor, chorea-ballismus, dystonia, tardive dyskinesia, myoclonus, tics and akathisia can be induced by many drugs. The drugs that are most frequently implicated in movement disorders are antipsychotics, calcium antagonists, orthopramides and substituted benzamides (e.g. metoclopramide, sulpiride, clebopride, domperidone), CNS stimulants, antidepressants, anticonvulsants, antiparkinsonian drugs and lithium. It is possible for a single drug to induce 2 or more types of movement disorders in the same patient. Movement disorders are not always reversible after drug withdrawal.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9098656     DOI: 10.2165/00002018-199716030-00004

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  618 in total

1.  Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease.

Authors:  L V Laitinen; A T Bergenheim; M I Hariz
Journal:  J Neurosurg       Date:  1992-01       Impact factor: 5.115

2.  Sertraline does not alter steady-state concentrations or renal clearance of lithium in healthy volunteers.

Authors:  G Apseloff; K D Wilner; D A von Deutsch; E B Henry; L M Tremaine; N Gerber; J D Lazar
Journal:  J Clin Pharmacol       Date:  1992-07       Impact factor: 3.126

3.  Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.

Authors:  J Jankovic; J Orman
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

4.  Physostigmine in choreiform movement disorders.

Authors:  D Tarsy; N Leopold; D S Sax
Journal:  Neurology       Date:  1974-01       Impact factor: 9.910

5.  The serotonin syndrome in a patient receiving sertraline after an ankle block.

Authors:  J S Jahr; J D Pisto; M C Gitlin; P T O'Neill
Journal:  Anesth Analg       Date:  1994-07       Impact factor: 5.108

6.  Movement disorders and depression due to flunarizine and cinnarizine.

Authors:  F E Micheli; M M Pardal; R Giannaula; M Gatto; I Parera; G Paradiso; M Torres; R Pikielny; J Pardal
Journal:  Mov Disord       Date:  1989       Impact factor: 10.338

7.  Persistent movement disorders induced by buspirone.

Authors:  P A LeWitt; A Walters; W Hening; D McHale
Journal:  Mov Disord       Date:  1993-07       Impact factor: 10.338

8.  Dyskinesias possibly induced by norpseudoephedrine.

Authors:  A Thiel; D Dressler
Journal:  J Neurol       Date:  1994-01       Impact factor: 4.849

9.  Increased incidence of levodopa therapy following metoclopramide use.

Authors:  J Avorn; J H Gurwitz; R L Bohn; H Mogun; M Monane; A Walker
Journal:  JAMA       Date:  1995-12-13       Impact factor: 56.272

10.  [A case of tuberculous pleurisy associated with myoclonus and Quincke's edema due to isoniazid and isoniazid sodium methanesulfonate].

Authors:  S Yagi; O Moriya; M Nakajima; S Umeki; J Hino; R Soejima
Journal:  Kekkaku       Date:  1989-06
View more
  17 in total

1.  Abnormal movements are associated with poor psychosocial functioning in adolescents at high risk for psychosis.

Authors:  Vijay A Mittal; Maria Jalbrzikowski; Melita Daley; Cristina Roman; Carrie E Bearden; Tyrone D Cannon
Journal:  Schizophr Res       Date:  2011-06-01       Impact factor: 4.939

2.  Lesson of the week: Akathisia: overlooked at a cost.

Authors:  Hiroko Akagi; T Manoj Kumar
Journal:  BMJ       Date:  2002-06-22

Review 3.  Practical considerations for the treatment of elderly patients with migraine.

Authors:  Paola Sarchielli; Maria Luisa Mancini; Paolo Calabresi
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

4.  [Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement].

Authors:  C Trenkwalder; S Boesch; A Ceballos-Baumann; D Dressler; K Eggert; T Gasser; H Honig; T Müller; H Reichmann; J P Sieb; A Storch; P Odin; W Poewe
Journal:  Nervenarzt       Date:  2008-04       Impact factor: 1.214

5.  The effect of a therapeutic lithium level on a stroke-related cerebellar tremor.

Authors:  Rachel A Orleans; Marc J Dubin; Kristopher A Kast
Journal:  BMJ Case Rep       Date:  2018-01-24

6.  Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism.

Authors:  P H Lee; J S Kim; D H Shin; S-N Yoon; K Huh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08-15       Impact factor: 10.154

Review 7.  Treatment strategies for dystonia.

Authors:  Leslie J Cloud; H A Jinnah
Journal:  Expert Opin Pharmacother       Date:  2010-01       Impact factor: 3.889

Review 8.  Drug-induced myoclonus: frequency, mechanisms and management.

Authors:  Félix Javier Jiménez-Jiménez; Inmaculada Puertas; María de Toledo-Heras
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  Catatonia in autism: implications across the life span.

Authors:  Angelina Kakooza-Mwesige; Lee E Wachtel; Dirk M Dhossche
Journal:  Eur Child Adolesc Psychiatry       Date:  2008-04-21       Impact factor: 4.785

10.  Parkinson's disease: genetics and beyond.

Authors:  N N Inamdar; D K Arulmozhi; A Tandon; S L Bodhankar
Journal:  Curr Neuropharmacol       Date:  2007       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.